The Filing Desk

ADMA Biologics vs Neurogene

ADMA Biologics ADMA · Neurogene NGNE · Biotechnology

ADMA Biologics' revenue grew 19.6% in its latest year, and Neurogene's fell 100.0%. Free cash flow was $28 million at ADMA Biologics and −$78 million at Neurogene.

Side by side

ADMA BiologicsNeurogene
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$510M$0M
Revenue growth19.6%−100.0%
Revenue growth a year, last 5 years64.6%—
Gross margin57.4%—
Operating margin37.5%—
Net margin28.8%—
Free cash flow$28M−$78M
Free cash flow margin5.5%—
Return on capital39.5%—
Net debt to EBITDA−0.1x—
Dividends and buybacks$32M$0M
Change in diluted share count0.6%21.4%
Last close$13.68$23.93
P/E at the last close17.8×—
Insider trades, last 12 monthsbought $468,294, sold $3.3 million—
Piotroski F-score5 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ADMA BiologicsNeurogene
Operating margin
Percent of revenue
ADMA BiologicsNeurogene
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ADMA BiologicsNeurogene

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ADMA Biologics and Neurogene pages.